Sign in

CIK 0001231457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
  1. 4 Open-market buy Director bought 2,500 shares
  2. 4 Open-market buy Director bought 8,000 shares
  3. 4 Open-market buy VP, Clinical Trial Operations bought 2,500 shares
  4. 4 Open-market buy President and CEO bought 200,000 shares
  5. 4 Open-market buy Head of Regulatory bought 1,250 shares
  6. 4 Open-market buy General Counsel bought 10,000 shares
  7. 4 Open-market buy Chief Financial Officer bought 31,250 shares
  8. 4 Open-market sale 10% owner sold 35,966 shares at an average $3.62 ($130,377)
  9. 4 Open-market sale 10% owner sold 19,944 shares at an average $3.78 ($75,300)
  10. 4 Open-market sale 10% owner sold 59,999 shares at an average $3.23 ($193,934)
  11. 4 Open-market sale 10% owner sold 44,395 shares at an average $3.51 ($155,647)
  12. 4 Open-market sale 10% owner sold 71,420 shares at an average $3.59 ($256,227)
  13. 4 Open-market sale VP, Clinical Trial Operations sold 32,535 shares at an average $13.16 ($428,180)
  14. 4 Open-market sale Director sold 9,000 shares at an average $13.22 ($118,969)
  15. 4 Open-market sale Director sold 9,000 shares at an average $13.38 ($120,387)
  16. 4 Open-market sale VP, Clinical Trial Operations sold 36,800 shares at $11.85 ($435,995)
  17. 4 Open-market sale VP, Clinical Trial Operations sold 18,665 shares at $10.26 ($191,555)
  18. 4 Open-market sale VP, Clinical Trial Operations sold 18,135 shares at an average $11.60 ($210,431)
  19. 4 Open-market sale 10% owner sold 5,704 shares at $19.40 ($110,638)
  20. 4 Open-market sale 10% owner sold 49,987 shares at $19.97 ($998,365)

Page 6 of 10 · 190 filings